Search Results - "Lewin, James B"

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons by Jiang, Tammy, Shanmugasundaram, Mathura, Božin, Ivan, Freedman, Mark S, Lewin, James B, Shen, Changyu, Ziemssen, Tjalf, Arnold, Douglas L

“…Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple…”
Get full text

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study by Singer, Barry A., Wray, Sibyl, Gudesblatt, Mark, Bumstead, Barbara, Ziemssen, Tjalf, Bonnell, Ashley, Scaramozza, Matthew, Levin, Seth, Shanmugasundaram, Mathura, Chen, Hailu, Mendoza, Jason P., Lewin, James B., Shankar, Sai L.

“…Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in…”
Get full text

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis” by Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.

Get full text

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod by Salter, Amber, Lancia, Samantha, Cutter, Gary, Marrie, Ruth Ann, Mendoza, Jason P., Lewin, James B., Fox, Robert J.

“…Background: Although the aggregate of data among patients with multiple sclerosis (MS) have shown similar efficacy between dimethyl fumarate (DMF) and…”
Get full text

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Williams, Mitzi J., Amezcua, Lilyana, Okai, Annette, Okuda, Darin T., Cohan, Stanley, Su, Ray, Parks, Becky, Mendoza, Jason P., Lewin, James B., Jones, Cynthia C.

“…Introduction Black or African American (black/AA) patients with multiple sclerosis (MS) are reported to exhibit greater disease severity compared with…”
Get full text

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis by Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.

“…Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral…”
Get full text

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM by Williams, Mitzi J., Amezcua, Lilyana, Chinea, Angel, Cohan, Stanley, Okai, Annette, Okuda, Darin T., Vargas, Wendy, Belviso, Nick, Božin, Ivan, Jiang, Xiaotong, Lewin, James B., Lyons, Jennifer, Shen, Changyu, England, Sarah M., Grimes, Nydjie

“…Introduction Multiple sclerosis (MS) clinical trials have included low numbers of patients from racial and ethnic minority populations; therefore, it is…”
Get full text

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Chinea, Angel, Amezcua, Lilyana, Vargas, Wendy, Okai, Annette, Williams, Mitzi J., Su, Ray, Parks, Becky, Mendoza, Jason P., Lewin, James B., Jones, Cynthia C.

“…Introduction Compared with the non-Hispanic/non-Latino population, Hispanic/Latino patients with multiple sclerosis (MS) are reported to exhibit greater…”
Get full text

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies by Amezcua, Lilyana, Mao-Draayer, Yang, Vargas, Wendy S., Farber, Rebecca, Schaefer, Sara, Branco, Filipe, England, Sarah M., Belviso, Nicholas, Lewin, James B., Mendoza, Jason P., Shankar, Sai L.

“…Introduction Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in phase 3 DEFINE and CONFIRM…”
Get full text

Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort by Krieger, Stephen, Zarif, Myassar, Bumstead, Barbara, Buhse, Marijean, Kaczmarek, Olivia, Srinivasan, Jared, Barros, Nuno, Sima, Diana, Ribbens, Annemie, Van Hecke, Wim, Lewin, James B., Mendoza, Jason P., Gudesblatt, Mark

“…Evaluate the real-world effect of dimethyl fumarate (DMF) on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis (RRMS) and compare…”
Get full text

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis by Jiang, Tammy, Ziemssen, Tjalf, Wray, Sibyl, Shen, Changyu, Söderbärg, Karin, Lewin, James B., Božin, Ivan, Freedman, Mark S.

“…Introduction Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing…”
Get full text

Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study by Bowen, James D., Stulc, Jessica, Hunter, Samuel F., Chen, Hailu, Lewin, James B., Scaramozza, Matthew, Bozin, Ivan, Then Bergh, Florian

“…Introduction Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are orally administered fumarate disease-modifying therapies (DMTs) for multiple sclerosis…”
Get full text

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis by Fox, Robert J., Chan, Andrew, Zhang, Annie, Xiao, James, Levison, Dane, Lewin, James B., Edwards, Michael R., Marantz, Jing L.

“…Objective: Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and fingolimod are approved oral disease-modifying treatments for…”
Get full text

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate by Gudesblatt, Mark, Bumstead, Barbara, Buhse, Marijean, Zarif, Myassar, Morrow, Sarah A., Nicholas, Jacqueline A., Hancock, Laura M., Wilken, Jeffrey, Weller, Joanna, Scott, Nicole, Gocke, Anne, Lewin, James B., Kaczmarek, Olivia, Mendoza, Jason P., Golan, Daniel

“…Introduction Switching disease-modifying therapy (DMT) may be considered for relapsing–remitting multiple sclerosis (RRMS) if a patient’s current therapy is no…”
Get full text

Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study by Hunter, Samuel F., Lindsey, John W., Osborne, Benjamin, Schreiber, Bethany, Branco, Filipe, Levin, Seth, Lewin, James B., Scaramozza, Matthew, Tian, Zhe, Antezana, Ariel

“…•Safety and efficacy of DRF in black vs non-Black patients was explored.○1057 patients enrolled in EVOLVE-MS-1; 72 (6.8 %) self-identified as black.○There were…”
Get full text

Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis by Bove, Riley, Applebee, Angela, Bawden, Katrina, Fine, Celeste, Shah, Anna, Avila, Robin L, Belviso, Nicholas, Branco, Filipe, Fong, Kinyee, Lewin, James B, Liu, Jieruo, England, Sarah M, Vignos, Megan

“…•Informative real-world data on DMT use in pregnancy are needed.•We evaluated DMT use and relapse in patients with MS before, during, and post-pregnancy.•DMT…”
Get full text

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence by Liseno, Jacob, Lager, Brittney, Miller, Catherine, Shankar, Sai L., Mendoza, Jason P., Lewin, James B.

“…Introduction Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is…”
Get full text

Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate by Salter, Amber, Lancia, Samantha, Cutter, Gary, Fox, Robert J, Marrie, Ruth Ann, Mendoza, Jason P, Lewin, James B

“…Delayed-release dimethyl fumarate (DMF) is effective in relapsing-remitting multiple sclerosis (RRMS), but long-term effects of DMF on disability and disease…”
Get full text

Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab by Nicholas, Jacqueline A, Gudesblatt, Mark, Garabedian, Meghan, Belviso, Nicholas, Shen, Changyu, Geremakis, Caroline, Shankar, Sai L, Mendoza, Jason P, Lewin, James B

“…•DMF-treated patients had a lower infection risk than matched OCR-treated patients.•Infection-related healthcare costs were lower for DMF- vs OCR-treated…”
Get full text

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison by Chan, Andrew, Cutter, Gary, Fox, Robert J, Xiao, James, Lewin, James B, Edwards, Michael R

“…Using matching-adjusted indirect comparison, we compared efficacy outcomes in patients with relapsing-remitting multiple sclerosis treated with delayed-release…”
Get full text